1Day C. Thiazolidinediones:a new class of antidiabetic drugs[J]. Diabet Med,1999,16(2) :179-192.
2Ovalle F, Bell DSH. Clinical evidence of thiazolidinodione-induccd improvclment of pancreatic B - ecll function in patients with type 2 dlabetcs mellitus [ J ]. Diabetes obcs Metab ,2002,4( 1 ) :56-59.
4Grunberger G Weston, WM Patwardhan R, et al. Rosiglitazo one or twice daily improves glycemic control in patients with type 2 diabetes, 1999, 48( suppl1 ) : 102.
6Fonseca V,Desouza C, Asnani S, et al. Nontraditional risk factors for cardiovascular disease in diabetes [ J ]. Endocr Rev,2004,25(1) :153-175.
7Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti -inflammatory effect of rosiglitazone[J]. J Clin Endocrinol Metab, 2004,89 ( 6 ) : 2 728-2 .735
2lmura H. A novel antidiabetic drug, troglitazone-reason for hope and concern. New Engl J Med, 1998,338:908-909.
3Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2.diabetic patients. Diabetic Med, 2000,17:40-47.
4Narayan KMV, Gregg EW, Fagot-Campagna A, et al. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract, 2000,50 ( Suppl 2 ) : S77-S84.
5Turner RC, Cull CA, Frighi V, Glycemic control with diet, sulfonylurea, mefformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies ( UKPDS 49), JAMA1999,281:2005-2012.
6Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulphonylureas. Diabetes, 2001,50 : A542.
7Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Met Res Rev, 2002,18 : 127-134.
8Barnett A. Rosiglitazone in type 2 diabetes: an evaluation in British lndo-Asian patients. Diabetic Med, 2001,18 :A40.
9Dogterum P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythrupoiesis or premature red cell destruction. Diabetes, 1999,48 :A98.
1Dandona P,Aljada A,Chaudhuri A,et al.The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes[J].J Clin Endocrinol Metab,2003,88:2422.
2Danesh J,Wheeler JG,Hirschfield GM,et al.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease[J].N Engl J Med,2004,350:1387.
3Winkler G,Lakatos P,Salamon F,et al.Elevated serum TNF-levels as a link between endothelial dysfunction and insulin resistance in normotensive obese subjects[J].Diabet Med,1999,16:207.
4Haffner SM,Greenberg AS,Weston WM,et al.Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus[J].Circulation,2002,106:679.
5Ilhan T,Berrin C,Erdem T,et al.Effect of rosiglitazone on insulin resistance,C-reactive protein and endothelial function in on-obese young women with polycystic ovary syndrome[J].European Journal of Endocrinology,2005,153:115.
